


Q/C Technologies, Inc. (QCLS)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001321834

Q/C Technologies, Inc. QCLS; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it  Rescans on file: E from Apr 21, 2020
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$41.2M	
Standard universe	inside revenue above \$1M and assets above \$10M	
Warnings	short runway, late filer, thin data, distress not computable: dilution, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Apr 29, 2026 163 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026	
Last close	\$0.64 2026-10-08; market equity \$5.2M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

Technologies, Inc. (the "Company") has historically been engaged in the development and commercialization of therapeutic platforms based on well-defined biological targets, including Isomyosamine and Supera-CBD. More recently, the Company has shifted its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based Company's core strategy is centered on leveraging an exclusive global licensing agreement with LightSolver Ltd. ("LightSolver") to deploy innovative laser processing units ("LPUs"), including the Company-branded qc-LPU100? (the "qc-LPU100").

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 47.4						

Gross profitability		not computable	32.2%			latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(8.2%)	(6.6%)	47.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31
Solvency, sleeve percentile 69.1						
Twelve-month failure probability		1.44%	0.07%	90.3	248	2026-06-30
Altman Z double-prime		(9.87)	(0.31)	61.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.00x	2.96x	56.1	839	2025-12-31
Growth and financing, sleeve percentile 14.4						
Revenue growth, three-year compound		not computable	10.0%			latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 6
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		32.9%	2.1%	14.4	704	2025-12-31
Net share issuance, one year		not computable	2.5%			prior share count is 15 days earlier

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 0.4 months
Late filer	found 4 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(44.1%)	8.0%	17
Distance from 52-week high	(90.8%)	(31.4%)	4
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(207.4%)	(1.0%)	4
Book value to price	3.09	0.28	99
Sales to price	0.30	0.31	49
Composite equity issuance, five years	799.0%	20.3%	99
Relative strength against the sector, log excess return	(0.79)	(0.14)	17

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$307,612
Operating cash flow, four quarters	-\$9.5M
Months of runway	0.4
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$465,766

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$478,747	2019-12-31	2020-03-25	10-K	0001493152-20-004650
2	assets	us-gaap:Assets	\$10.9M	2019-12-31	2021-03-01	10-K	0001493152-21-005129
3	net income	us-gaap:NetIncomeLoss	-\$11.6M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$9.1M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
5	assets	us-gaap:Assets	\$41.2M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
6	assets	us-gaap:Assets	\$21.4M	2024-12-31	2026-04-15	10-K	0001493152-26-016872
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.6M	2019-12-31	2020-03-25	10-K	0001493152-20-004650
8	gross profit	us-gaap:GrossProfit	\$127,285	2018-12-31	2020-03-25	10-K	0001493152-20-004650
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.7M	2018-12-31	2020-03-25	10-K	0001493152-20-004650
10	gross profit	us-gaap:GrossProfit	\$948,580	2017-12-31	2019-04-01	10-K	0001493152-19-004590
11	revenue	us-gaap:Revenues	\$3.4M	2017-12-31	2018-07-13	10-K/A	0001493152-18-009979
12	gross profit	us-gaap:GrossProfit	\$1.9M	2016-12-31	2018-07-13	10-K/A	0001493152-18-009979
13	revenue	us-gaap:Revenues	\$3.0M	2016-12-31	2018-07-13	10-K/A	0001493152-18-009979
14	gross profit	us-gaap:GrossProfit	\$1.2M	2015-12-31	2017-04-11	10-K	0001493152-17-003722
15	revenue	us-gaap:Revenues	\$2.1M	2015-12-31	2017-04-11	10-K	0001493152-17-003722
16	current assets	us-gaap:AssetsCurrent	\$16.6M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
17	current liabilities	us-gaap:LiabilitiesCurrent	\$5.5M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$144.1M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
19	operating income	us-gaap:OperatingIncomeLoss	-\$9.8M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
20	book equity	us-gaap:StockholdersEquity	\$21.8M	2025-12-31	2026-04-15	10-K	0001493152-26-016872
21	liabilities	us-gaap:Liabilities	\$16.4M	2025-12-31	2026-04-15	10-K	0001493152-26-016872

22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$112,951	2015-12-31	2017-04-11	10-K	0001493152-17-003722
23	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$299,995	2015-12-31	2017-04-11	10-K	0001493152-17-003722
24	operating income	us-gaap:OperatingIncomeLoss	-\$9.7M	2015-12-31	2017-04-11	10-K	0001493152-17-003722
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$9.6M	2015-12-31	2017-04-11	10-K	0001493152-17-003722
26	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$269,344	2015-12-31	2017-04-11	10-K	0001493152-17-003722
27	current assets	us-gaap:AssetsCurrent	\$6.5M	2015-12-31	2017-04-11	10-K	0001493152-17-003722
28	current liabilities	us-gaap:LiabilitiesCurrent	\$1.7M	2015-12-31	2017-04-11	10-K	0001493152-17-003722
29	current assets	us-gaap:AssetsCurrent	\$13.1M	2014-12-31	2016-03-30	10-K	0001493152-16-008364
30	current liabilities	us-gaap:LiabilitiesCurrent	\$1.8M	2014-12-31	2016-03-30	10-K	0001493152-16-008364
31	assets	us-gaap:Assets	\$17.9M	2023-12-31	2025-04-11	10-K	0001641172-25-003814
32	assets	us-gaap:Assets	\$17.5M	2022-12-31	2024-04-01	10-K	0001493152-24-012533
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,853,429	2026-04-27	2026-04-29	10-K/A	0001493152-26-019663
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,853,429	2026-04-12	2026-04-15	10-K	0001493152-26-016872